CRISPR Therapeutics AG (LTS:0VRQ) LT-Debt-to-Total-Asset: 0.28 (As of Mar. 2026)


LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
46 GF Score
Price $59.25
GF Value $2.74
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG LT-Debt-to-Total-Asset?

CRISPR Therapeutics AG LTS:0VRQ 46 LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 46/100 and a GF Value™ of $2.74 (Significantly Overvalued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CRISPR Therapeutics AG's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.28.

CRISPR Therapeutics AG's long-term debt to total assets ratio increased from Mar. 2025 (0.09) to Mar. 2026 (0.28). It may suggest that CRISPR Therapeutics AG is progressively becoming more dependent on debt to grow their business.

CRISPR Therapeutics AG  (LTS:0VRQ) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CRISPR Therapeutics AG LT-Debt-to-Total-Asset Related Terms

CRISPR Therapeutics AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG LT-Debt-to-Total-Asset Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.10 0.10 0.09 0.08

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.10 0.09 0.08 0.28
LTS:0VRQ
46GF Score
CRISPR Therapeutics AG LTS:0VRQ
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG LT-Debt-to-Total-Asset Calculation

CRISPR Therapeutics AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=188.168/2265.243
=

CRISPR Therapeutics AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=769.03/2725.82
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.28 mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a LT-Debt-to-Total-Asset of 0.28 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's LT-Debt-to-Total-Asset too high?
CRISPR Therapeutics AG's current LT-Debt-to-Total-Asset is 0.28. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's LT-Debt-to-Total-Asset compare to ORKA and TVTX?
CRISPR Therapeutics AG's LT-Debt-to-Total-Asset of 0.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current LT-Debt-to-Total-Asset is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.74, compared to a current price of $59.25 — trading 2062.4% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.28. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current LT-Debt-to-Total-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $59.25 is trading 2062.4% above its estimated GF Value™ of $2.74. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • LT-Debt-to-Total-Asset: 0.28
  • GF Value™: $2.74 vs. price of $59.25 (2062.4% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score

Get the complete analysis for LTS:0VRQ

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.25
Price
$2.74
GF Value